-
公开(公告)号：US06784190B2
公开(公告)日：2004-08-31
申请号：US09916977
申请日：2001-07-27
申请人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , George D. Hartman , Cecilia A. Hunt , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Garry R. Smith , Jiabing Wang
发明人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , George D. Hartman , Cecilia A. Hunt , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Garry R. Smith , Jiabing Wang
IPC分类号： A61K3147
CPC分类号： C07D401/06 , C07D401/12 , C07D471/04 , C07D495/04
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3，alphavbeta5和/或alphavbeta6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化 ，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
-
公开(公告)号：US6048861A
公开(公告)日：2000-04-11
申请号：US212082
申请日：1998-12-15
申请人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , George D. Hartman , Cecilia A. Hunt , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Garry R. Smith , Jiabing Wang
发明人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , George D. Hartman , Cecilia A. Hunt , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Garry R. Smith , Jiabing Wang
IPC分类号： C07D401/06 , C07D401/12 , C07D471/04 , C07D495/04 , C07D519/00 , A61K31/435 , A61K31/44
CPC分类号： C07D401/06 , C07D401/12 , C07D471/04 , C07D495/04
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体αvβ3，αvβ5和/或αvβ6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，并抑制血管再狭窄， 糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
-
公开(公告)号：US6017926A
公开(公告)日：2000-01-25
申请号：US212079
申请日：1998-12-15
申请人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Jiabing Wang
发明人： Ben C. Askew , Paul J. Coleman , Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Robert S. Meissner , Michael A. Patane , Jiabing Wang
IPC分类号： A61K31/66 , A61K45/06 , C07D401/14 , C07D471/04 , C07D519/00 , A61K31/435
CPC分类号： C07D401/14 , A61K31/66 , A61K45/06 , C07D471/04
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地，本发明的化合物是整联蛋白受体αvβ3，αvβ5和/或αvβ6的拮抗剂，并且可用于抑制骨吸收，治疗和预防骨质疏松症和抑制血管再狭窄，糖尿病 视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病和肿瘤生长和转移。
-
公开(公告)号：US06472403B2
公开(公告)日：2002-10-29
申请号：US09766148
申请日：2001-01-19
申请人： Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Aiwen Li , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Jiabing Wang , Michael A. Patane
发明人： Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Aiwen Li , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Jiabing Wang , Michael A. Patane
IPC分类号： A61K3144
CPC分类号： C07D213/73 , A61K45/06 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10
摘要： The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
摘要翻译： 本发明涉及其新颖的咪唑啉酮衍生物，其合成及其作为αphav整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体α2和/或阿尔巴博5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症， 炎症性关节炎，病毒性疾病，癌症和转移性肿瘤生长。
-
公开(公告)号：US07153862B2
公开(公告)日：2006-12-26
申请号：US10618414
申请日：2003-07-10
申请人： Ben C. Askew , Michael J. Breslin , Mark E. Duggan , John H. Hutchinson , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Michael A. Patane
发明人： Ben C. Askew , Michael J. Breslin , Mark E. Duggan , John H. Hutchinson , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Michael A. Patane
IPC分类号： A61K31/55 , A61K31/505 , C07D471/02 , C07D265/36 , C07D498/02
CPC分类号： C07D213/73 , A61K45/06 , C07D239/26 , C07D239/42 , C07D239/48 , C07D401/06 , C07D403/06 , C07D405/06 , C07D471/04 , C07D471/10
摘要： The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
摘要翻译： 本发明涉及其新的链烷酸衍生物，它们的合成及其作为αphav整合素受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3和/或alphavbeta5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎性关节炎 ，癌症和转移性肿瘤生长。
-
公开(公告)号：US06693101B2
公开(公告)日：2004-02-17
申请号：US09767471
申请日：2001-01-23
申请人： Ben C. Askew , Michael J. Breslin , Mark E. Duggan , John H. Hutchinson , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Michael A. Patane
发明人： Ben C. Askew , Michael J. Breslin , Mark E. Duggan , John H. Hutchinson , Robert S. Meissner , James J. Perkins , Thomas G. Steele , Michael A. Patane
IPC分类号： A61K3144
CPC分类号： C07D213/73 , A61K45/06 , C07D239/26 , C07D239/42 , C07D239/48 , C07D401/06 , C07D403/06 , C07D405/06 , C07D471/04 , C07D471/10
摘要： The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
摘要翻译： 本发明涉及其新的链烷酸衍生物，它们的合成及其作为αphav整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3和/或alphavbeta5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎性关节炎 ，癌症和转移性肿瘤生长。
-
公开(公告)号：US06297249B1
公开(公告)日：2001-10-02
申请号：US09453847
申请日：1999-12-02
IPC分类号： C07D40106
CPC分类号： C07D401/06 , C07D401/12 , C07D471/04 , C07D495/04
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3，alphavbeta5和/或alphavbeta6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化 ，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
-
公开(公告)号：US09029343B2
公开(公告)日：2015-05-12
申请号：US13991321
申请日：2011-12-05
IPC分类号： C07H19/16 , C07H19/167 , C07D473/34
CPC分类号： C07H19/16 , C07D473/34 , C07H19/167
摘要： Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.
摘要翻译： 公开了化合物，含有这些化合物的药物组合物，以及化合物和组合物作为组蛋白甲基转移酶调节剂的用途，以及用于治疗受组蛋白甲基转移酶活性调节影响的疾病。
-
公开(公告)号：US20140315790A1
公开(公告)日：2014-10-23
申请号：US13865157
申请日：2013-04-17
摘要： The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
摘要翻译： 本申请描述了可用于治疗，预防和/或改善疾病的有机化合物。
-
公开(公告)号：US20140046242A1
公开(公告)日：2014-02-13
申请号：US14060055
申请日：2013-10-22
申请人： Mike Jaffe , Gary Cook , Perry Calias , Michael A. Patane
发明人： Mike Jaffe , Gary Cook , Perry Calias , Michael A. Patane
IPC分类号： A61K41/00 , A61K9/00 , A61F9/00 , A61K31/573
CPC分类号： A61K9/0048 , A61F9/0008 , A61K9/0009 , A61K31/573 , A61K41/00 , A61N1/044 , A61N1/0448 , A61N1/303
摘要： Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
摘要翻译： 本文公开了适合通过眼部离子电渗疗法递送的地塞米松或其前药的制剂及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.056 秒)